NCT01835132View on ClinicalTrials.gov

Gevokizumab for Active Scleritis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

February 29, 2016

Conditions
Scleritis
Interventions
DEVICE

Gevokizumab

Subcutaneous injection of 60 mg gevokizumab

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
collaborator

The Emmes Company, LLC

INDUSTRY

lead

National Eye Institute (NEI)

NIH

NCT01835132 - Gevokizumab for Active Scleritis | Biotech Hunter | Biotech Hunter